StockData
Starling Oncology, Inc. logo

Starling Oncology, Inc. (STLN) stock

STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 6/30
$6.53−0.12 (-1.80%)

Close on Oct 30, 2026Market cap $665.51MP/E –Yield –

Earnings

Starling Oncology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 12, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
$161.30M
+34.6% on a year earlier
EPS, Q2 FY2026
-$0.08
-$0.15 a year earlier
Latest guidance
Raised
Aug 6, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Starling Oncology's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours$161.30M+34.6%-$0.08Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours$147.40M+41.2%–Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026during market hours$142.00M+42.0%-$0.06Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025during market hours$136.60M+36.7%-$0.14Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025during market hours$119.80M+21.5%-$0.15Release
Q1 FY2025ended Mar 31, 2025May 14, 2025during market hours$104.40M+9.9%-$0.21Release
Q4 FY2024ended Dec 31, 2024Mar 24, 2025before the open$100.00M+16.3%–Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024during market hours$99.90M+21.8%-$0.18Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024during market hours$98.60M+23.2%-$0.17Release
Q1 FY2024ended Mar 31, 2024May 14, 2024during market hours$95.00M+25.0%-$0.22Release
Q4 FY2023ended Dec 31, 2023Mar 27, 2024during market hours$86.00M+21.1%-$0.21Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Starling Oncology's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Adjusted EBITDAnon-GAAPQ3 FY2026$500.00K – $1.50M–NewAug 6, 2026
RevenueFY2026$650.00M – $670.00M$630.00M – $650.00MRaisedAug 6, 2026
RevenueGAAPFY2026$630.00M – $650.00M–NewMar 12, 2026
Gross ProfitGAAPFY2026$97.00M – $107.00M–NewMar 12, 2026
Adjusted EBITDAnon-GAAPFY2026$2.00M – $7.00M$0 – $9.00MNarrowedAug 6, 2026
Adjusted EBITDAnon-GAAPFY2026$0 – $9.00M–NewMar 12, 2026
Free Cash Flownon-GAAPFY2026$5.00M – $15.00M$5.00M – $15.00MReaffirmedAug 6, 2026
Free Cash Flownon-GAAPFY2026-$15.00M – $5.00M–NewMar 12, 2026
Capitation revenueFY2026$150.00M–NewJan 12, 2026
Gross ProfitFY2026$105.00M – $110.00M$97.00M – $107.00MRaisedAug 6, 2026
total revenueFY2028+20%–NewJan 12, 2026
Capitation revenue as a percentage of total revenueFY202830%–NewJan 12, 2026
Dispensary revenue as a percentage of total revenueFY202850%–RaisedJan 12, 2026

Guidance history

Every forecast Starling Oncology put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 6, 2026Adjusted EBITDAQ3 FY2026$500.00K – $1.50MNew
Aug 6, 2026Adjusted EBITDAFY2026$2.00M – $7.00MNarrowed
Aug 6, 2026Free Cash FlowFY2026$5.00M – $15.00MReaffirmed
Aug 6, 2026Medical Loss Ratiothe next twelve months80% – 90%–
Aug 6, 2026Gross ProfitFY2026$105.00M – $110.00MRaised
Aug 6, 2026RevenueFY2026$650.00M – $670.00MRaised
Aug 6, 2026capitated revenueFY2026$150.00MLowered
May 7, 2026Adjusted EBITDAQ2 FY2026-$1.00M – $1.00MNew
May 7, 2026Adjusted EBITDAFY2026$0 – $9.00MReaffirmed
May 7, 2026Free Cash FlowFY2026$5.00M – $15.00MNew
May 7, 2026Gross ProfitFY2026$97.00M – $107.00MLowered
May 7, 2026RevenueFY2026$630.00M – $650.00MReaffirmed
May 7, 2026capitated revenueFY2026$150.00MLowered
Mar 12, 2026Adjusted EBITDAQ1 FY2026-$3.00M – -$1.00MNew
Mar 12, 2026Adjusted EBITDAFY2026$0 – $9.00MNew
Mar 12, 2026Free Cash FlowFY2026-$15.00M – $5.00MNew
Mar 12, 2026Gross ProfitFY2026$97.00M – $107.00MNew
Mar 12, 2026RevenueFY2026$630.00M – $650.00MNew
Jan 12, 2026Adjusted EBITDAFY2026$0 – $9.00MNew
Jan 12, 2026Capitation revenueFY2026$150.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Starling Oncology filed with the SEC as exhibits to Form 8-K or 6-K

  1. Starling Oncology Reports Second Quarter
    Results
  2. The Oncology Institute Rebrands as Starling Oncology
    Update
  3. The Oncology Institute Completes Strategic Refinancing with
    Update
  4. The Oncology Institute Reports First
    Results
  5. 8-K exhibit EX-99.1
    Update
  6. The Oncology Institute Reports Fourth
    Results
  7. The Oncology Institute Appoints Kim Tzoumakas to Board of
    Update
  8. Quarterly results release
    Results
  9. Oncology Institute Announces Addition of Board Member Mark Stolper
    Update
  10. The Oncology Institute Announces Resignation of Board Member
    Update
  11. 8-K exhibit EX-99.1
    Update
  12. The Oncology Institute Reports Third
    Results
  13. The Oncology Institute Reports Second
    Results
  14. Changes to Board of Directors
    Update
  15. 8-K exhibit EX-99.1
    Update